Skip to main content
SpringerLink
Log in

Evaluation of the Reveal® rapid AST system to assess the susceptibility of Pseudomonas aeruginosa from blood cultures

  • Original Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

This study was set up to assess the performance of the Reveal® rapid AST system to determine the drug susceptibility of Pseudomonas aeruginosa strains directly from blood cultures. Two hundred fully sequenced clinical P. aeruginosa strains were selected for the evaluation, of which 26.5% (n = 53) produced transferable β-lactamases, and 2.0 to 33.0% had susceptibility levels close to the EUCAST 2021 breakpoints of 11 commonly used antipseudomonal antibiotics. The Reveal® AST system was run with a commercial MIC microplate designed for fast-growing Gram-negative bacilli (Microscan Neg MDR MIC 1), and was compared to the manually operated GN6F MIC microdilution panel from Thermo Fisher, as a comparator method. The Reveal® AST system provided MIC results for the 11 antipseudomonal antibiotics tested within a mean time to result of 6 h 22 min. By comparison with the GN6F panel, the overall rates of categorical agreement (CA), very major errors (VME), major errors (ME), and minor errors (mE for meropenem only) were 96.1%, 1.6%, 4.2%, and 0.6%, respectively. The Specific Reveal® AST system appears to be a reliable and fast technology to determine the susceptibility of P. aeruginosa to antibiotics, including those with resistance levels near categorical breakpoints, directly from blood cultures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

All the data are available on request from the corresponding author (PP). Complementary information is provided as supplemental material (Table S1).

Code availability

Not applicable.

References

  1. van Delden C (2007) Pseudomonas aeruginosa bloodstream infections: how should we treat them? Int J Antimicrob Agents 30(Suppl 1):S71-75

    Article  Google Scholar 

  2. Micek ST, Lloyd AD, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH (2005) Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 49:1306–1311

    Article  CAS  Google Scholar 

  3. Recio R, Mancheno M, Viedma E, Villa J, Orellana MA, Lora-Tamayo J, Chaves F (2020) Predictors of mortality in bloodstream infections caused by Pseudomonas aeruginosa and impact of antimicrobial resistance and bacterial virulence. Antimicrob Agents Chemother 64(2):e01759–19

  4. van Belkum A, Burnham CD, Rossen JWA, Mallard F, Rochas O, Dunne WM Jr (2020) Innovative and rapid antimicrobial susceptibility testing systems. Nat Rev Microbiol 18(5):299–311

    Article  Google Scholar 

  5. Giacobbe DR, Giani T, Bassetti M, Marchese A, Viscoli C, Rossolini GM (2020) Rapid microbiological tests for bloodstream infections due to multidrug resistant Gram-negative bacteria: therapeutic implications. Clin Microbiol Infect 26(6):713–722

    Article  CAS  Google Scholar 

  6. Lim SH, Mix S, Xu Z, Taba B, Budvytiene I, Berliner AN, Queralto N, Churi YS, Huang RS, Eiden M, Martino RA, Rhodes P, Banaei N (2014) Colorimetric sensor array allows fast detection and simultaneous identification of sepsis-causing bacteria in spiked blood culture. J Clin Microbiol 52(2):592–598

    Article  Google Scholar 

  7. Tibbetts R, George S, Burwell R, Rajeev L, Rhodes PA, Singh P, Samuel L (2022) Performance of the Reveal rapid antibiotic susceptibility testing system on Gram-negative blood cultures at a large urban hospital. J Clin Microbiol 60(6):e0009822

    Article  Google Scholar 

  8. Akerlund A, Jonasson E, Matuschek E, Serrander L, Sundqvist M, Kahlmeter G, Group RS (2020) EUCAST rapid antimicrobial susceptibility testing (RAST) in blood cultures: validation in 55 European laboratories. J Antimicrob Chemother 75(11):3230–3238

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank Martin Rottman for reviewing the manuscript.

Funding

DF, MB, and KJ are public officials whose salaries were supported by the Centre Hospitalier Universitaire of Besançon, France. Specific Diagnostics (LR, PR, PS) provided the material and reagents necessary for the study, as well as the funds to hire JC as laboratory technician.

Author information

Authors and Affiliations

  1. Laboratoire de Bactériologie, UMR 6249 CNRS ChronoEnvironnement, Université de Franche-Comté, 19 Rue Ambroise Paré, 25030, Besançon, France

    J. Couchot & P. Plésiat

  2. Centre National de Référence de La Résistance Aux Antibiotiques, Centre Hospitalier Universitaire, Besançon, France

    D. Fournier, M. Bour & K. Jeannot

  3. Specific Diagnostics, San José, USA

    L. Rajeev, P. Rhodes & P. Singh

Authors
  1. J. Couchot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Fournier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Bour
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Rajeev
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Rhodes
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K. Jeannot
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P. Plésiat
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

As follows: study design (PP, DF, KJ, LR, PS), bacterial collections (DF, KJ, PP), experimental work (JC, MB, DF), data analysis (DF, PP), draft preparation (PP, DF, KJ).

Corresponding author

Correspondence to P. Plésiat.

Ethics declarations

Ethics approval

This in vitro study did not require specific ethical review or consent.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent for publication

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors JC, DF, MB, KJ, and PP declare to have no specific conflicts of interest. LR, PR, and PS belonged to the staff of Specific Diagnostics at the time of experiments. They did not interfere with the process of data production or their interpretation.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (XLSX 52 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Couchot, J., Fournier, D., Bour, M. et al. Evaluation of the Reveal® rapid AST system to assess the susceptibility of Pseudomonas aeruginosa from blood cultures. Eur J Clin Microbiol Infect Dis 42, 359–363 (2023). https://doi.org/10.1007/s10096-023-04556-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-023-04556-2

Keywords

Search

Navigation